{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:19:09Z","timestamp":1792387149465,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019851","name":"Aldeyra Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40123-026-01379-0","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:34:20Z","timestamp":1775900060000},"page":"1807-1821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04735393","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nathan M.","family":"Radcliffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239271","author":"K Tsubota","year":"2020","unstructured":"Tsubota K, Pflugfelder SC, Liu Z, Baudouin C, Kim HM, Messmer EM, et\u00a0al. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21239271.","journal-title":"Int J Mol Sci"},{"key":"1379_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","volume":"202","author":"R Dana","year":"2019","unstructured":"Dana R, Bradley JL, Guerin A, Pivneva I, Stillman I, Evans AM, et\u00a0al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019;202:47\u201354. https:\/\/doi.org\/10.1016\/j.ajo.2019.01.026.","journal-title":"Am J Ophthalmol"},{"key":"1379_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091458","author":"AC Britten-Jones","year":"2024","unstructured":"Britten-Jones AC, Wang MTM, Samuels I, Jennings C, Stapleton F, Craig JP. Epidemiology and risk factors of dry eye disease: considerations for clinical management. Medicina (Kaunas). 2024. https:\/\/doi.org\/10.3390\/medicina60091458.","journal-title":"Medicina (Kaunas)"},{"key":"1379_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/vision9010013","author":"E Cheng","year":"2025","unstructured":"Cheng E, Han K, Chen Y, Asbell P, Ying GS, The Dream Research Group. Associations of the severity of dry eye symptoms and signs with quality of life in the Dry Eye Assessment and Management (DREAM) study. Vision. 2025. https:\/\/doi.org\/10.3390\/vision9010013.","journal-title":"Vision"},{"key":"1379_CR5","unstructured":"American Academy of Ophthalmology. How to manage a dry eye disease flare-up. https:\/\/www.aao.org\/eye-health\/tips-prevention\/treatment-symptom-relieve-dry-eye-flare. Accessed 5 Jan 2026."},{"issue":"1","key":"1379_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","volume":"124","author":"EJ Holland","year":"2017","unstructured":"Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, et\u00a0al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.025.","journal-title":"Ophthalmology"},{"key":"1379_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2025.1700163","volume":"5","author":"X Bian","year":"2025","unstructured":"Bian X, Ma J, Liu Y, Feng Y, Liu Z, Zhang B, et\u00a0al. Cyclosporine A in the treatment of dry eye disease: a narrative review. Front Ophthalmol. 2025;5:1700163. https:\/\/doi.org\/10.3389\/fopht.2025.1700163.","journal-title":"Front Ophthalmol"},{"issue":"9","key":"1379_CR8","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s40123-025-01190-3","volume":"14","author":"C Koetting","year":"2025","unstructured":"Koetting C, Schweitzer J, Nichols KK, McDonald M, Starr CE, Chan CC, et\u00a0al. Real-world experience with lifitegrast ophthalmic solution in patients with dry eye disease: a provider survey in the USA and Canada. Ophthalmol Ther. 2025;14(9):2109\u201324. https:\/\/doi.org\/10.1007\/s40123-025-01190-3.","journal-title":"Ophthalmol Ther"},{"key":"1379_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.09.018","author":"GR Pattar","year":"2025","unstructured":"Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, et\u00a0al. Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of phase 3 pivotal COMET-2 and COMET-3 studies. Ophthalmology. 2025. https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.018.","journal-title":"Ophthalmology"},{"issue":"4","key":"1379_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/jop.2020.0087","volume":"37","author":"D Clark","year":"2021","unstructured":"Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021;37(4):193\u20139. https:\/\/doi.org\/10.1089\/jop.2020.0087.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"1379_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/aos.14892","volume":"100","author":"V Navel","year":"2022","unstructured":"Navel V, Sapin V, Henrioux F, Blanchon L, Labb\u00e9 A, Chiambaretta F, et\u00a0al. Oxidative and antioxidative stress markers in dry eye disease: a systematic review and meta-analysis. Acta Ophthalmol. 2022;100(1):45\u201357. https:\/\/doi.org\/10.1111\/aos.14892.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1379_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17925\/USOR.2023.17.1.31","volume":"17","author":"TS Swartz","year":"2023","unstructured":"Swartz TS, Powell W. Reproxalap for the treatment of dry eye disease. US Ophthalmic Review. 2023;17(1):31\u20135. https:\/\/doi.org\/10.17925\/USOR.2023.17.1.31.","journal-title":"US Ophthalmic Review"},{"issue":"1","key":"1379_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-025-00497-3","volume":"15","author":"A Elgadi","year":"2025","unstructured":"Elgadi A, Abdalmotalib MM, Noorallah T, Abdelazim E, Mohammed FAM. Reproxalap in patients with seasonal allergic conjunctivitis: a systematic review and meta-analysis. J Ophthalmic Inflamm Infect. 2025;15(1):39. https:\/\/doi.org\/10.1186\/s12348-025-00497-3.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"9","key":"1379_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3109\/02713683.2015.1098707","volume":"41","author":"W Choi","year":"2016","unstructured":"Choi W, Lian C, Ying L, Kim GE, You IC, Park SH, et\u00a0al. Expression of lipid peroxidation markers in the tear film and ocular surface of patients with non-Sjogren syndrome: potential biomarkers for dry eye disease. Curr Eye Res. 2016;41(9):1143\u20139. https:\/\/doi.org\/10.3109\/02713683.2015.1098707.","journal-title":"Curr Eye Res"},{"issue":"2","key":"1379_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00417-024-06587-7","volume":"263","author":"S Patil","year":"2025","unstructured":"Patil S, Sawale G, Ghuge S, Sathaye S. Quintessence of currently approved and upcoming treatments for dry eye disease. Graefes Arch Clin Exp Ophthalmol. 2025;263(2):269\u201378. https:\/\/doi.org\/10.1007\/s00417-024-06587-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1379_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajo.2021.01.011","volume":"226","author":"D Clark","year":"2021","unstructured":"Clark D, Tauber J, Sheppard J, Brady TC. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22\u201331. https:\/\/doi.org\/10.1016\/j.ajo.2021.01.011.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1379_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100938","volume":"6","author":"S Garg","year":"2026","unstructured":"Garg S, Donnenfeld E, Sheppard J, Epitropoulos A, Brady TC. Reproxalap improves ocular redness, tear production, and symptoms in a pivotal dry eye disease chamber trial. Ophthalmol Sci. 2026;6(1):100938. https:\/\/doi.org\/10.1016\/j.xops.2025.100938.","journal-title":"Ophthalmol Sci"},{"key":"1379_CR18","unstructured":"Inotek Pharmaceuticals: Why do eye drops cause discomfort and how to minimize It. 2024. https:\/\/www.inotekcorp.com\/why-do-eye-drops-cause-discomfort-and-how-to-minimize-it-understanding-composition-irritation-ph-levels-allergic-reactions-and-application-techniques.html. Accessed 1 Nov 2025."},{"issue":"2","key":"1379_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","volume":"121","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Torkildsen GL, Lonsdale JD, D\u2019Ambrosio FA Jr, McLaurin EB, Eiferman RA, et\u00a0al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475\u201383. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.015.","journal-title":"Ophthalmology"},{"issue":"12","key":"1379_CR20","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","volume":"122","author":"J Tauber","year":"2015","unstructured":"Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, et\u00a0al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423\u201331. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.001.","journal-title":"Ophthalmology"},{"issue":"3","key":"1379_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5582\/ddt.2025.01048","volume":"19","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang W, Sun F. Acoltremon: the first TRPM8 agonist approved for the treatment of dry eye disease. Drug Discov Ther. 2025;19(3):210\u20131. https:\/\/doi.org\/10.5582\/ddt.2025.01048.","journal-title":"Drug Discov Ther"},{"key":"1379_CR22","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.2147\/opth.S327691","volume":"15","author":"D McMullin","year":"2021","unstructured":"McMullin D, Clark D, Cavanagh B, Karpecki P, Brady TC. A post-acute ocular tolerability comparison of topical reproxalap 0.25% and lifitegrast 5% in patients with dry eye disease. Clin Ophthalmol. 2021;15:3889\u2013900. https:\/\/doi.org\/10.2147\/opth.S327691.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1379_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615\u201321. https:\/\/doi.org\/10.1001\/archopht.118.5.615.","journal-title":"Arch Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01379-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:08:22Z","timestamp":1778749702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01379-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: Nathan M. Radcliffe is a consultant for AbbVie, Alcon, Bausch\u2009+\u2009Lomb, Harrow, Tarsus, and Th\u00e9a. John Sheppard is a consultant for Bausch\u2009+\u2009Lomb, GmbH, Harrow, and Novaliq. Blake Simmons was an investigator in other studies of reproxalap. Desiree Owen and Ashley Nguyen are employees of AbbVie and may own stock\/stock options. Bill Cavanagh and Todd C. Brady are employees of Aldeyra Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The clinical trial was performed in accordance with Good Clinical Practice, applicable regulations, and the principles of the Declaration of Helsinki. An institutional review board (Alpha IRB, San Clemente, CA, USA) or independent ethics committee approved the protocol, informed consent forms, and recruitment materials at each site before patient enrollment, and all patients provided written informed consent at screening before undergoing any trial-related procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}